JP Morgan Chase
LIMN icon

JP Morgan Chase’s Liminatus Pharma LIMN Stock Holding History

JP Morgan Chase’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$536 Buy
+137
New +$690 ﹤0.01% 7673

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Cheviot Value Management
Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

JP Morgan Chase's LIMN Position: Q3 2026 in Review

JP Morgan Chase opened a new position in Liminatus Pharma (LIMN) in Q3 2026: 137 shares worth $536. The stake represents ﹤0.01% of the portfolio and ranks #7673 among its holdings.

9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

  • JP Morgan Chase held 137 shares of Liminatus Pharma worth $536 as of Q3 2026.
  • Liminatus Pharma was a new JP Morgan Chase position in Q3 2026.
  • Liminatus Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #7673 holding.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.